NIH Notice Number: NOT-OD-17-072 establishes the FY 2017 Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels.
From the Notice:
This revised Notice supersedes NOT-OD-16-062, and establishes stipend levels for fiscal year (FY) 2017 Kirschstein-NRSA awards for undergraduate and predoctoral trainees and fellows, as shown in the table below. The Training Related Expenses and Institutional Allowances for predoctoral trainees and fellows and the Tuition and Fees for all educational levels remain unchanged.
The budgetary categories described in this Notice apply only to Kirschstein-NRSA awards made with FY 2017 funds. All FY 2017 awards previously issued using FY 2016 stipend levels (NOT-OD-16-062) will be revised to adjust stipends to the FY 2017 level.
Appointments to institutional training grants that have already been awarded in FY 2017 must be amended to reflect the FY 2017 stipend levels once the training grant award has been adjusted by the NIH. Amended appointments must be submitted through xTrain in the eRA Commons. Retroactive adjustments or supplementation of stipends or other budgetary categories with Kirschstein-NRSA funds for an award made prior to October 1, 2016 are not permitted.
Note: The FY 2017 stipend and other budgetary levels for postdoctoral trainees and fellows was issued on December 15, 2016: NOT-OD-17-003
Stipends for FY 2017
Effective with all Kirschstein-NRSA awards made on or after October 1, 2017, the following annual stipend levels apply to all individuals receiving support through institutional research training grants or individual fellowships, including the Maximizing Access to Research Career (MARC) and Building Infrastructure Leading to Diversity (BUILD) programs.
Undergraduates in the MARC and BUILD Programs: For institutional training grants (T34, TL4), two stipend levels may be used for undergraduate candidates: Freshmen/Sophomores and Juniors/Seniors.
Stipend for FY 2017
Predoctoral Trainees and Fellows: For institutional training grants (T32, T35, T90, TL1) and individual fellowships (F30, F31, F99), one stipend level is used for all predoctoral candidates, regardless of the level of experience.
Years of Experience
Tuition and Fees, Training Related Expenses, and Institutional Allowance for Kirschstein-NRSA Recipients
The NIH will provide funds for Tuition and Fees, Training Related Expenses, and Institutional Allowance as detailed below.
A. Tuition and Fees
Undergraduate and Predoctoral Trainees and Fellows: For institutional training grants (T32, T34, T35, T90, TL1, TL4) and individual fellowships (F30, F31, F99), an amount per predoctoral trainee equal to 60% of the level requested by the applicant institution, up to $16,000 per year, will be provided. If the trainee or fellow is enrolled in a program that supports formally combined, dual-degree training (e.g., MD/PhD, DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), the amount provided per trainee or fellow will be 60% of the level requested, up to $21,000 per year.
B. Training Related Expenses on Institutional Training Grants
For institutional training grants (T32, T35, T90, TL1), these expenses (including health insurance costs) for predoctoral trainees will be paid at the amounts shown below for all competing and non-competing awards made with FY 2017 funds.
C. Institutional Allowance for Individual Fellows
This allowance for predoctoral fellows will be paid at the amounts shown below for all competing and non-competing awards made with FY 2017 funds.
Institutional Allowance for individual fellows (F30, F31, F99) sponsored by non-Federal Public, Private, and Non-Profit Institutions (Domestic & Foreign, including health insurance):
Institutional Allowance for individual fellows (F30, F31, F99) sponsored by Federal and For-Profit Institutions (including health insurance):
Current stipend levels are to be used in the preparation of future competing and non-competing NRSA institutional training grant and individual fellowship applications. They will be administratively applied to all applications currently in the review process.
NRSA support is limited to 5 years for predoctoral trainees (6 years for dual-degree training, e.g., MD/PhD, DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD).
It should be noted that the maximum amount that NIH will award to support the compensation package for a graduate student research assistant remains at the zero level postdoctoral stipend, as described in NOT-OD-02-017.
Frequently Asked Questions Related to NRSA Tuition, Fees, and Health Insurance Policies: http://grants.nih.gov/training/nrsa_tuition_q&a.htm.
This message serves as a reminder for everyone at MUSC to adhere to the policy on Appendix Materials in funding applications submitted to the National Institutes of Health (NIH), the Agency for Healthcare Research and Quality (AHRQ), or the National Institute for Occupational Safety and Health (NIOSH).
These federal agencies will administratively withdraw applications that include any disallowed materials in the Appendices. Such an oversight will prohibit the application from getting peer reviewed and scored.
This information has been added to the ORSP web page for quick reference (http://academicdepartments.musc.edu/research/orsp/policies_procedures/appendix_materials_NIH_AHRQ_NIOSH).
NOTE: the NIH FAQ link (https://grants.nih.gov/grants/policy/appendix_policy.htm) has been included to help clarify what is or is not allowed to be included in the Appendix Materials.
Notice NOT-OD-16-129 alerted the scientific research community of the elimination of most appendix materials for applications submitted to NIH, AHRQ or NIOSH for due dates on or after January 25, 2017.
The NIH, AHRQ, and NIOSH strive to ensure fairness in peer review for all grant applicants by specifying the types and amount of application material that are accepted for peer review. At the same time, these agencies appreciate both the need for applications to provide sufficient information to allow for an informed, expert review process and the importance of limiting the burden on peer reviewers.
Elimination of most appendix materials is intended to rectify inequities in the peer review process that can arise from submission of inappropriate or excessive appendix materials by some applicants and consideration of appendix materials in peer review by some, but not all reviewers.
Appendix materials in peer review
All information submitted with an application except the cover letter, assignment request form and appendix information are assembled into a single application image for funding consideration. The different sections within the application image are specified in the application instructions and correspond to the standard review criteria.
Allowable appendix materials
Beginning with applications submitted to the NIH, AHRQ, or NIOSH for due dates on or after January 25, 2017, the only allowable appendix materials are:
For applications proposing clinical trials (unless the FOA provides other instructions for these materials):
For all applications:
Consequences for submitting disallowed appendix materials
Applications submitted for due dates on or after January 25, 2017 will be withdrawn and not reviewed if they are submitted with appendix materials that are not specifically listed in this Notice or the FOA as allowed or required.
FAQs on the NIH/AHRQ/NIOSH Appendix Policy
Notice NOT-OD-17-062 announced a transition from the current NIH grant application forms (“FORMS-D”) to the next iteration of forms (“FORMS-E”) for due dates on or after January 25, 2018.
Highlights of the new FORMS-E will include:
Application guides for FORMS-E application packages will be posted to the How to Apply - Application Guide page no later than October 25, 2017.
All NIH "parent" announcements that use standard due dates will be expired and reissued with new FOA numbers, FORMS-E application packages and instructions. The FORMS-E parent announcements will be posted no later than 60 days before their standard due date. For a transition period, both FORMS-D and FORMS-E parent announcements will be active. Applicants must choose the announcement with the appropriate application package for their due date (see table below).
All active FOAs with due dates both before and after January 25, 2018 will be updated to add FORMS-E application packages between October 25, 2017 and November 25, 2017. For a transition period, both FORMS-D and FORMS-E application packages will be active. Applicants must choose the appropriate application package for their due date when presented with both FORMS-D and FORMS-E application packages on the same FOA (see table below).
If your due date is…
You must use…
On or before January 24, 2018, including:
FORMS-D application package
On or after January 25, 2018, including:
FORMS-E application package
Additional guide notices for individual FOAs with unique due date considerations will be issued as needed and referenced in the Related Notices section of each FOA.
Form Update Timing for Administrative Supplement, Successor-in-Interest (Type 6) and Change of Institution (Type 7) Parent Announcements
Parent announcements for administrative supplements and post award administrative actions (successor-in-interest and change of institution applications) do not have set due dates and, consequently, will follow a different timeline than other parent announcements.
The FOAs in the table below will be reissued with new FOA numbers, FORMS-E application packages and instructions on January 25, 2018. Applications started on or after January 25, 2018 must use the new FOAs and FORMS-E application packages.
These FOAs will expire on February 25, 2018 giving applicants one month to complete their initiated FORMS-D applications.
Change of Grantee Organization (Type 7 Parent)
Successor-in-Interest (Type 6 Parent)
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Admin Supp)
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)
Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp)
Applications Proposing Clinical Trials
As previously announced, all applications involving clinical trials must be submitted to FOAs specifically designed for clinical trials beginning with due dates on or after January 25, 2018 (NOT-OD-16-147, NOT-OD-17-043).
NIH will take the following steps to accommodate this new policy:
A new notice from the NIH (Reporting Preprints and Other Interim Research Products, NOT-OD-17-050) indicates that interim research products, including preprints, can soon be cited where other research products are cited. This includes the NIH Biosketch and Section C of the Research Performance Progress Report (RPPR), among others. The change is effective for all applications submitted for the May 25, 2017 due date and beyond, and for RPPRs submitted on or after May 25, 2017.
What are Interim Research Products?
NIH defines interim research products as complete, public research products that are not final. A common form is the preprint, which is a complete and public draft of a scientific document. Preprints are typically manuscripts written in the style of a peer-reviewed journal article that have not been subject to peer review. Scientists issue preprints to speed dissemination, establish priority, obtain feedback, and offset publication bias.
Citing Interim Research Products
When citing an interim research product, applicants and awardees must include the Digital Object Identifier and the Object type (e.g. preprint, protocol) in the citation. They should also list any information about the document version (e.g. most recent date modified), and if relevant, the date the product was cited.
Bar DZ, Atkatsh K, Tavarez U, Erdos MR, Gruenbaum Y, Collins FS. Biotinylation by antibody recognition- A novel method for proximity labeling. BioRxiv 069187 [Preprint]. August 11, 2016 [cited 2017 Jan 12]. Available from: https://doi.org/10.1101/069187.
For more information, see: NIH NOT-OD-17-050: Reporting Preprints and Other Interim Research Products.
In October 2016, the NIH requested information on the use of interim research products and standards for reporting them (Request for information (RFI): Including Preprints and Interim Research Products in NIH Applications and Reports, NOT-OD-17-006). The NIH received 351 responses and nearly all respondents supported increasing the use of interim research products in NIH award processes. Specific benefits of interim research products include speeding dissemination of results, enhancing the rigor of the research and avoiding publication bias. For more information about the responses, see the Background and Public Comments section of: NIH NOT-OD-17-050: Reporting Preprints and Other Interim Research Products.
Per NIH notice NOT-OD-17-049, the new NIH salary cap is $187,000 effective January 8, 2017.
Salaries up to this new $187,000 level are allowed to be charged starting January 8, 2017, to NIH funded grants provided the necessary funds are available.
NOTE: No additional funds will be provided by NIH.
Once the Department of Health and Human Services Appropriation for FY 2017 is enacted, NIH will publish the annual Notice of legislative mandates to provide information on any statutory provisions that limit the use of NIH grant funds in FY 2017. Additional guidance on the salary cap will also be provided at that time.
For those planning to make payroll adjustments due to this salary cap increase, we encourage using February 1st, 2017, as the start date for any changes. Start dates other than the first day of the month may lead to errors due to the manual calculations required.
When preparing all future NIH grant proposals, please use the new salary cap maximum. Both the ORSP Proposal Preparation page and Cayuse data are being updated to reflect the new NIH Salary Cap level.
Effective February 9, 2017, if the recipient organization has submitted a renewal application on or before the date by which a Final Research Performance Progress Report (Final-RPPR) would be required for the current competitive segment, then submission of an "Interim-RPPR" via eRA Commons is now required. Based on this requirement, the NIH will discontinue the policy for renewal applications whereby, “whether funded or not,” the progress report contained in the renewal application may serve in lieu of a separate final progress report.
An Interim-RPPR link for the grant will appear in the Status tab in eRA Commons after the period of performance end date has passed. In the event that the renewal application is funded, NIH will treat the Interim-RPPR as the annual performance report for the final year of the previous competitive segment. If the renewal application is not funded, the Interim-RPPR will be treated by NIH staff as the institution's Final-RPPR.
As stated in NOT-OD-17-022, the Interim-RPPR must be submitted via the eRA Commons no later than 120 calendar days from the period of performance end date. If a recipient fails to comply with this reporting requirement, NIH may take one or more enforcement actions, such as a decision to withhold a non-competing continuation award, consistent with NIHGPS Chapter 8.5.2. NIH will maintain the business rule in the RPPR module enabling institutional signing officials (SOs), at their discretion, to delegate submission of the Final RPPR or Interim-RPPR to the Program Director/Principal Investigator (PD/PI).
Further guidance is provided through the scenarios below outlining the process of when to submit a Final or Interim-RPPR.
Status of Competing Renewal Application
Competing Renewal not submitted
Submit a Final-RPPR no later than 120 calendar days from the period of performance end date.
Competing Renewal submitted
Submit an Interim-RPPR no later than 120 calendar days from the period of performance end date. If the competing renewal is funded, NIH will treat the Interim-RPPR as the annual performance report for the final year of the previous competitive segment.
Competing Renewal submitted but not funded
Submit an Interim-RPPR no later than 120 calendar days from the period of performance end date. If the competing renewal is not funded, NIH will treat the Interim-RPPR as the institution's Final-RPPR. To reduce burden NIH will not require recipients to submit an additional Final-RPPR if the renewal application is not funded.
Reminder: Effective January 2017, NIH requires recipients to report on Project Outcomes in Section I of the Interim and Final-RPPR. Therefore, in each scenario listed above, Project Outcomes must be provided by the recipient in order for the recipient to submit their final report in eRA Commons. Otherwise, eRA Commons will not allow recipients to submit the required report and recipients will be considered non-compliant.
NOTE: Implementation of the Final RPPR for Small Business Innovation and Research (SBIR) and Small Business Technology Transfer (STTR) grants will occur approximately 2 months after implementation for all other NIH grants due to unique final reporting requirements under the Small Business Administration's SBIR/STTR Policy Directive.
NIH Notice NOT-OD-17-033 announces how Inauguration Day will affect deadlines that fall on Friday, January 20, as that is considered a Federal holiday for most NIH staff.
Please be aware and plan accordingly as NIH will have limited staffing on this date.
Impact on Support
• eRA Service Desk - open with reduced staffing
• General Grants Information support desk - unavailable
• Institute/Center staff - unavailable
Impact on Due Dates
• All application due dates that fall on January 20, 2017 will move to January 23, 2017, including (but not limited to) due dates for the following funding opportunity announcements:
o PAR-15-068 - NIDDK Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34)
o RFA-CA-16-502 - Limited Competition: The Chernobyl Tissue Bank - Coordinating Center (U24)
Impact on Systems
• All eRA systems will remain operational
Please share this information with everyone (faculty, students/postdocs and staff) involved with grant proposal submissions or grant awards administration in your areas.
Should anyone have questions, please contact your assigned ORSP Grant Administrator or call 843-792-3838 for assistance.
NIH Notice NOT-OD-17-030 updates the NIH/AHRQ font guidance for applications due on or after January 25, 2017.
The Notice updates NIH’s recommended font list. Please note that NIH no longer requires that black text be used within grant application attachments.
For applications submitted for due dates on or after January 25, 2017, text in PDF attachments must follow these minimum requirements:
Since some PDF converters may reduce font size, it is important to confirm that the final PDF document complies with the font requirements.
The following fonts are recommended, although other fonts (both serif and non-serif) are acceptable if they meet the above requirements.
Legibility is of paramount importance. Applications that include PDF attachments that do not conform to the minimum requirements listed above may be withdrawn from consideration.
NIH Notice NOT-OD-17-022 announced NIH’s implementation of Final Research Performance Progress Reports (Final RPPR or F-RPPR) effective January 1, 2017.
The Final RPPR will replace the Final Progress Report (FPR) and will be submitted via a new eRA Commons module.
A significant change with implementation of the F-RPPR is that in order to maximize public transparency, NIH will not maintain the current Type 2 policy which in accordance with NIHGPS Chapter 8.6.2 states that "whether funded or not" the progress report contained in the Type 2 application may serve in lieu of a separate final progress report.
NIH will request that organizations submit an "Interim-RPPR" while their renewal application (Type 2) is under consideration. In the event that the Type 2 is funded, NIH will treat the Interim-RPPR as the annual performance report for the final year of the previous competitive segment. If the Type 2 is not funded, the Interim-RPPR will be treated by NIH staff as the institution's Final-RPPR.
NIH is aligning its reporting requirement with other Federal research agencies and therefore will not be making any changes to the deadline for submitting the final report- i.e., the Final RPPR or Interim-RPPR must be submitted via eRA Commons no later than 120 calendar days from the period of performance end date. If a recipient fails to comply with this reporting requirement, NIH may take one or more enforcement actions, such as a decision not to make a non-competing continuation award, consistent with NIHGPS Chapter 8.5.2. NIH also plans to maintain the business rule in the RPPR module enabling institutional signing officials (SOs), at their discretion, to delegate submission of the Final RPPR or Interim-RPPR to the Program Director/Principal Investigator (PD/PI).
Note: Implementation of the Final RPPR for Small Business Innovation and Research (SBIR) and Small Business Technology Transfer (STTR) grants will occur approximately 2 months after implementation for all other NIH grants due to unique final reporting requirements under the Small Business Administration's SBIR/STTR Policy Directive.
FAQs and additional information pertaining to NIH's implementation of the F-RPPR will be available on the NIH RPPR website.
NIH has a longstanding policy that states any applicant requesting $500,000 or more in direct costs (excluding consortium F&A costs) in any one budget period within a competitive segment is required to contact the NIH Institute or Center (IC) Program Official (PO), in writing or by telephone, as early as possible during development of the application but no later than 6 weeks before submission for prior approval. Since NIH supports projects with large budgets, the purpose of this policy is for fiscal planning and therefore it provides NIH ICs the appropriate amount of time to consider the possibility of such awards as early as possible in the budget and program planning process.
Notice number NOT-OD-17-005 informs NIH applicants that requests to submit an unsolicited application that will exceed $500,000 in direct costs will now have an option to submit this request electronically through eRA Commons, under a new Prior Approval Module.